Ernexa Therapeutics Inc. Interest Expense
Ernexa Therapeutics Inc. (ERNA) reported Interest Expense of $614.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-03-14
- Ernexa Therapeutics Inc. interest expense for fiscal 2023 was $614.00K, a 1946.67% increase from fiscal 2022.
- Ernexa Therapeutics Inc. interest expense for fiscal 2022 was $30.00K.
- Ernexa Therapeutics Inc. interest expense for fiscal 2014 was $223.00K, a 757.69% increase from fiscal 2013.
- Ernexa Therapeutics Inc. interest expense for fiscal 2013 was $26.00K, a 40.91% decline from fiscal 2012.
| Period end | Interest Expense 12 month |
|---|---|
| 2023-12-31 | $614.00K 10-K · filed 2024-03-14 |
| 2022-12-31 | $30.00K 10-K · filed 2024-03-14 |
| 2014-12-31 | $223.00K 10-K · filed 2015-03-27 |
| 2013-12-31 | $26.00K 10-K · filed 2015-03-27 |
| 2012-12-31 | $44.00K 10-K · filed 2014-03-31 |
| 2011-12-31 | $52.00K 10-K · filed 2013-03-29 |
| 2010-12-31 | $101.00K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |